Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on improving outcomes for people affected by kidney disease, announced on November 17, 2026, that the United States Patent and Trademark Office (USPTO) has issued a new patent for its drug Vafseo® (vadadustat). The patent, U.S. Patent No. 12,797,375, is eligible for listing in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) and carries a term extending to January 18, 2043.
John P. Butler, Chief Executive Officer of Akebia Therapeutics, expressed optimism about the patent’s contribution to the company’s vadadustat intellectual property portfolio. He stated, “We are pleased to continue to build the vadadustat patent portfolio with this new patent that has a term to January 2043, and which we believe enhances the long-term value of Vafseo.” Butler further emphasized the company’s confidence in Vafseo’s potential to become the standard of care for anemia treatment in chronic kidney disease, supported by robust clinical outcomes and strong patent protection.
The newly granted patent specifically relates to a method of treatment involving the modulation of drug-drug interactions during vadadustat therapy. This complements the existing portfolio of fourteen vadadustat patents currently listed in the Orange Book, which have expiration dates ranging from 2027 to 2036.
Vafseo, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, received U.S. Food and Drug Administration (FDA) approval in March 2024 for the treatment of anemia due to chronic kidney disease in adults who have been on dialysis for at least three months. Since January 2025, Vafseo has been commercially available in the United States. Notably, no other oral HIF-PH inhibitors are approved or in development for anemia treatment in the U.S. market.
Akebia Therapeutics, founded in 2007 and headquartered in Cambridge, Massachusetts, is a fully integrated biopharmaceutical company dedicated to improving the lives of people impacted by kidney disease. More information about the company is available on its website, www.akebia.com.
Vafseo® (vadadustat) tablets are administered once daily and work by activating the physiological response to hypoxia, stimulating endogenous erythropoietin production, thereby increasing hemoglobin and red blood cell production to manage anemia. The drug is approved for use in 37 countries worldwide.
The FDA-approved indication for Vafseo is the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. However, Vafseo has not been demonstrated to improve quality of life, fatigue, or patient well-being.
Vafseo is not indicated as a substitute for red blood cell transfusions in patients requiring immediate anemia correction or for patients with anemia due to CKD who are not on dialysis.
The drug carries warnings about increased risks of thrombotic vascular events, including major adverse cardiovascular events (MACE). Targeting hemoglobin levels above 11 g/dL is expected to increase the risk of death and thrombotic events, similar to risks observed with erythropoietin stimulating agents (ESAs). No clinical trial has identified a safe hemoglobin target, dose, or dosing strategy that avoids these risks. Therefore, the lowest effective dose sufficient to reduce red blood cell transfusions is recommended.
Additional safety concerns include increased risks of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access. Rapid rises in hemoglobin greater than 1 g/dL over two weeks can elevate these risks. Vafseo should be avoided in patients with recent myocardial infarction, cerebrovascular events, or acute coronary syndrome within three months prior to treatment initiation.
Hepatotoxicity has been reported in less than 1% of patients, including severe cases of hepatocellular injury with jaundice. Elevated liver enzymes (ALT, AST) and bilirubin have been observed in a small percentage of patients. Liver function tests should be monitored before treatment, monthly for the first six months, and thereafter as clinically indicated. Vafseo is not recommended for patients with cirrhosis or active acute liver disease.
Hypertension worsening was reported in 14% of Vafseo-treated patients compared to 17% in patients treated with darbepoetin alfa, with serious hypertension events occurring in approximately 3% of patients in both groups. Cases of hypertensive crisis, including encephalopathy and seizures, have also been reported. Blood pressure should be monitored and antihypertensive therapy adjusted as necessary.
Seizures occurred in 1.6% of patients treated with Vafseo, matching the incidence in the darbepoetin alfa group. Patients should be monitored for new-onset seizures, premonitory symptoms, or changes in seizure frequency.
This new patent grant reinforces Akebia Therapeutics’ position in the anemia treatment market for chronic kidney disease patients on dialysis, providing extended intellectual property protection that supports the commercial lifecycle of Vafseo through 2043.
Akebia Therapeutics Secures New U.S. Patent Extending Protection for Vafseo® (vadadustat) Through 2043 Akebia Therapeutics has obtained a new U.S. patent for Vafseo® (vadadustat), an oral treatment for anemia due to chronic kidney disease (CKD) in dialysis patients. Issued by the USPTO on November 17, 2026, the patent ex... Read the full IIPLA article: https://iipla.org/news/akebia-therapeutics-secures-new-u-s-patent-extending-protection-for-vafseo-vadadustat-through-2043